Key takeaways for Vermont
- • GLP-1 RAs and GLP-1/GIP agonists are first-line injectables after metformin in 2025 ADA guidelines.
- • HbA1c reductions of 1.0-2.0 points are typical at maintenance dose.
- • Semaglutide and tirzepatide have proven cardiovascular benefits in T2D.
- • Green Mountain Care coverage rules apply for Type 2 Diabetes patients in Vermont — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Type 2 Diabetes
GLP-1 receptor agonists lower HbA1c by 1.0-2.0 percentage points on average, promote weight loss, and carry cardiovascular benefits validated in dedicated outcomes trials. Evidence grade: A (level 1, multiple RCTs and meta-analyses). The ADA Standards of Care 2025 list GLP-1 RAs (or GLP-1/GIP dual agonists like tirzepatide) as preferred when glycemic, weight, or CV/renal goals are not met on metformin. Always paired with diet, activity, and ongoing labs — not standalone therapy.
Vermont-specific context
Vermont has telehealth access concentrated in Burlington, South Burlington, Rutland metros, with additional reach to Essex Junction and Bennington. University of Vermont Medical Center is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.healthvermont.gov.
Vermonttelehealth & pricing rules
- • Vermont requires a live video consultation before a GLP-1 prescription.
- • Vermont allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Vermont: ~$309/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.